Otrivin Moisturising Formula (Xylometazoline Hydrochloride)

Xylometazoline acts as an α‑adrenergic agonist. When applied to the nasal lining, it binds to α‑receptors on the vascular smooth muscle, causing vasoconstriction. This reduces swelling of the nasal tissues, opens the airway, and eases breathing.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s age, condition, and response. Typically, a few sprays per nostril are used, but the exact regimen should follow the prescriber’s instructions.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Otrivin’s active ingredient, xylometazoline, is a selective α‑adrenergic agonist offering rapid, localized decongestion with minimal systemic effects. Compared with older agents such as phenylephrine, xylometazoline often provides longer‑lasting relief and a lower incidence of systemic side effects when used as directed.

Store the nasal spray at room temperature, below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product integrity.

The product is administered as a nasal spray. The user gently inserts the tip into each nostril and presses the pump to deliver the recommended number of sprays, usually while keeping the head upright. No oral ingestion is involved.

Serious risks, though rare, include severe hypertension, cardiac arrhythmias, nasal ulceration or perforation with prolonged use, and anaphylactic reactions. Patients should discontinue use and seek medical attention if they experience any of these severe symptoms.

Individuals with known hypersensitivity to xylometazoline or any formulation component should avoid the product. It is also contraindicated in patients with severe hypertension, coronary artery disease, or those taking monoamine oxidase inhibitors. Children under two years of age should not use it unless specifically directed by a physician.